HLS Therapeutics (TSE:HLS) Trading Down 1.2% – Here’s What Happened

Shares of HLS Therapeutics Inc. (TSE:HLS) fell 1.2% during mid-day trading on Thursday . The stock traded as low as C$3.92 and last traded at C$3.96. 27,905 shares changed hands during mid-day trading, an increase of 72% from the average session volume of 16,203 shares. The stock had previously closed at C$4.01.

Analyst Upgrades and Downgrades

Separately, Raymond James upped their price target on HLS Therapeutics from C$4.00 to C$5.00 in a report on Friday, November 22nd.

HLS Therapeutics Stock Up 1.0 %

The company has a market capitalization of C$88.99 million, a PE ratio of -4.01 and a beta of 1.07. The company has a quick ratio of 1.01, a current ratio of 1.56 and a debt-to-equity ratio of 86.50. The firm has a 50-day moving average of C$4.07 and a two-hundred day moving average of C$3.72.

HLS Therapeutics Company Profile

HLS Therapeutics Inc is a specialty pharmaceutical company. It is focused on the acquisition and commercialization of branded pharmaceutical products in the North American markets. The company is focused on treatment products for the central nervous system (CNS), and cardiovascular specialties. The company products include Clozaril, Absorica, Vascepa, CSAN Pronto, Trinomia and Perseris.